NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/21/2023
Back to search
Official data from USPTO
ZEAL & ZEALAND PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000090144485Class
5, 10, 16, 35, 41, 42, 44, 45
Filing
90144485
Registration
6986947
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
02/24/2023
Trademark type
Combined
Nice classes
5, 10, 16, 35, 41, 42, 44, 45
Filing date
08/28/2020
Registration date
02/21/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/21/2023
Last transaction
02/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-06-00
First use in commerce
2021-06-00
Drawing code
3
Owner type
99
Owner location
Søborg, DK
Examiner
VENGURLEKAR, SAGAR S
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "ZEAL&" with each letter appearing in white, in a blue circle, an overlapped grey circle, an overlapped yellow circle, an overlapped turquoise circle, a red circle, from left to right, with the grey wording "ZEALAND PHARMA" written below.
Holders and representatives
Holders
Zealand Pharma A/S
Representatives
Shannon Marie McKeon DYKEMA GOSSETT PLLC
Technical classification
Nice Classes
Class 5Class 10Class 16Class 35Class 41Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
(Based on 44(e)) Pharmaceutical preparations for the treatment of diabetesobesity and gastrointestinal diseases; synthetic peptides for pharmaceuticals purposes for the treatment of diabetesobesity and gastrointestinal diseases; pharmaceutical preparations for the treatment of diseasesillnesses and ailments in humanspharmaceutical preparations for treating endocrine disordersimmunity disordersnutritional and metabolic diseasessuch as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseasessuch as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune systemsuch as complement inhibitors; apparatus and instruments containing pharmaceutical preparationssubstances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes containing insulin or glucagon or analogues of those
Class 10
(Based on Use in Commerce) Medical apparatus and instrumentsdiabetes management devicesinfusion and injection devicesinfusion pumpsinfusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; blood glucose monitors for medical purposes; glucose monitor accessoriestransmittersreceiversmedical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods; wearable health devices for insulin monitoring
Class 16
(Based on Use in Commerce) printed pharmaceutical information leaflets in the field of diabetesobesity and gastrointestinal diseases; printed publicationsbooksmagazinesperiodicals and manualsall in the field of diabetesobesity and gastrointestinal diseases; printed instructional or teaching matter in the field of diabetesobesity and gastrointestinal diseases; printed instructional and teaching materials about diagnosing and treatment of diabetesobesity and gastrointestinal diseases; printed guidelines for diagnosing and treatment of diabetesobesity and gastrointestinal diseases
Class 35
(Based on 44(e)) Marketing services; customer relationship management; business administrative services for medical referrals; patient relationship management services; business administration of pharmacy and pharmaceutical benefit plans
Class 41
(Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetesobesity and gastrointestinal diseases; providing educational seminarseducational exhibitionsconferences and training coursesall in the field of diabetesobesity and gastrointestinal diseases; educational seminarseducational exhibitionsconferences and instructional services relating to medical treatments in the field of diabetesobesity and gastrointestinal diseases; educational servicesorganizing and conducting educational programscoaching and training services for patients and healthcare professionals related to management of diabetesobesity and gastrointestinal diseases
Class 42
(Based on 44(e)) Scientific and technological servicesresearch and design in the field of medicinepharmaceuticalsgeneticsbiology and biotechnology; industrial analysis and research services in the field of medicinepharmaceuticalsgeneticsbiology and biotechnology; medicalbiologicalbiotechnologicalgeneticlaboratory and pharmaceutical researchdesign and development services; laboratory research in the field of medicinepharmaceuticalsgeneticsbiology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetesobesity and gastrointestinal diseases; providing websites featuring technology that enables users to recordtrackgenerate reports regarding the conditiontreatment and the management of diabetesobesity and gastrointestinal diseases; computer servicesproviding a website featuring technology that enables users to obtain data concerning medical analysis and management of diabetesobesity and gastrointestinal diseases
Class 44
(Based on 44(e)) Medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseasesillnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseasessuch as short bowel syndrome and ulcerative colitis; clinical trials; medical consulting servicesproviding patient adherence programs to patients suffering from diabetesobesity or gastrointestinal diseases; providing web-based on-line portals that provide a patient adherence program to patients suffering from diabetesobesity or gastrointestinal diseases; medical information servicesproviding information relating to the treatment of diabetesobesity or gastrointestinal diseases; medical advisory servicesproviding advisory services relating to the treatment of diabetesobesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetesobesity or gastrointestinal diseases; medical information and advice in relation to treatment planningincluding information and advice provided via the Internetdatabases and application software; consultancy services relating to the aforesaid
Class 45
(Based on 44(e)) Licensing of patent and intellectual property rights arising from medical and pharmaceutical research and development activities; licensing of proprietary intellectual property
Publications
History of USPTO decisions and trademark events.
52 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/21/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/14/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/13/2023
DOCK
ASSIGNED TO EXAMINER
12/17/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/15/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/15/2022
IUAF
USE AMENDMENT FILED
10/27/2022
EISU
TEAS STATEMENT OF USE RECEIVED
10/27/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/23/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/09/2022
EX1G
SOU EXTENSION 1 GRANTED
06/07/2022
EXT1
SOU EXTENSION 1 FILED
06/07/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/07/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
02/04/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/14/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/19/2021
PUBO
PUBLISHED FOR OPPOSITION
10/19/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/29/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/13/2021
ALIE
ASSIGNED TO LIE
09/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/11/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
09/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
09/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/11/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
09/09/2021
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
09/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/24/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/24/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/24/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/24/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/24/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/05/2021
GNFR
FINAL REFUSAL E-MAILED
08/05/2021
CNFR
FINAL REFUSAL WRITTEN
08/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/03/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/27/2021
GNRT
NON-FINAL ACTION E-MAILED
07/27/2021
CNRT
NON-FINAL ACTION WRITTEN
07/27/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/25/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/25/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/25/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/07/2021
GNRT
NON-FINAL ACTION E-MAILED
01/07/2021
CNRT
NON-FINAL ACTION WRITTEN
01/07/2021
DOCK
ASSIGNED TO EXAMINER
12/30/2020
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/02/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/01/2020
NWAP
NEW APPLICATION ENTERED
09/01/2020
Continuous trademark protection
Get notified about every new filing that threatens ZEAL & ZEALAND PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.